Rick Matthews/LikedIn
Mar 9, 2026, 13:49
Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
Rick Matthews, Senior Vascular Consultant at Argon Medical Devices, Inc., shared on LinkedIn:
”We talk a lot about ‘clearing clot today’ with modern mechanical thrombectomy/PMT options, but the long game is what patients live with: recurrent ipsilateral DVT risk, valve injury, chronic outflow obstruction, and structured follow-up.
Are you routinely documenting Villalta at 3–6 months after DVT (and repeating at ~12 months), or is it still inconsistent across services?
PTS symptoms often reflect the net effect of obstruction plus reflux plus microvascular injury—so the pathway has to be stepwise.
My simple escalation triggers (baked into any VTE program):
- Villalta ≥10 / meaningful functional limitation
- Venous claudication
- Skin changes or ulcer
- New/worsening swelling – rule out recurrent DVT first”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS